In Brief: Urologix/Boston Scientific
This article was originally published in The Gray Sheet
Executive SummaryUrologix/Boston Scientific: Enter distribution agreement under which Boston Scientific obtains exclusive right to market Urologix' T3 (Transurethral Thermo-ablation Therapy) system for treatment of benign prostatic hyperplasia in all markets outside the U.S. and Japan. BSC begins exhibiting the T3 system at the British Association of Urological Surgeons meeting the week of June 24 in Edinburgh, Scotland. In the U.S., Urologix plans to submit a premarket approval application later this year for the T3 system. Nihon Kohden holds marketing rights in Japan, where an application for marketing approval already is pending...
You may also be interested in...
HBW Product Launches: New Chapter Collagen, Alkamind Acid-Kicking, GNC China, Tetra Bio Canada, More
GNC, Harbin launch supplements in China following regulatory approval; Bee Gone expands with allergy swabs; Bed, Bath & Beyond expands distribution of CBDMedic personal care products promoted by Rob Gronkowski; Tetra Bio has Canadian OK For hemorrhoid and pain relief OTCs, US and European pending; Agrozen offers Urban Daze CBD products; New Chapter portfolio expansion also includes fermented vitamins, elderberry supplements and magnesium; and Alkamind’s Acid-Kicking Coffee Alkalizer creamers help neutralize acid from coffee.
In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.